DUBLIN, Calif, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2012 third quarter financial results on Tuesday, October 30, 2012. James S.J. Manuso, PhD, chairman and chief executive officer, and the Astex Pharmaceuticals management team will provide details of the Company's financial results and any revised outlook for the future.
A press release will be issued following the close of the market on October 30th. The Company will host a webcast conference call to discuss the results at 4:30 p.m. ET. A live webcast of the call may be accessed through the Events Calendar in the Investors section of the Company's website at www.astx.com. A webcast replay of the conference call will be available shortly following the event. Alternatively, a replay of the conference call may be accessed by dialing (855) 859-2056 (domestic) and (404) 537-3406 (international); the replay passcode number is 53673255. The webcast replay will be available for 30 days, and the telephone replay will be available for 7 days.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273